Damora Therapeutics (DMRA) Profit After Tax (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Profit After Tax data on file, last reported at -$27.8 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 996.84% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$235.1 million (down 1171.09% YoY), and the FY2025 full-year result was -$209.8 million, down 878.77% from the prior year.
• Profit After Tax for Q1 2026 stood at -$27.8 million, up from -$200.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$2.5 million in Q1 2025 and bottomed at -$200.7 million in Q4 2025.
• The 5-year median for Profit After Tax is -$8.1 million (2023), against an average of -$21.1 million.
• The widest annual swing landed in 2024, when Profit After Tax jumped 57.85%; it then plunged 2877.84% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$14.1 million in 2022, then soared by 53.98% to -$6.5 million in 2023, then decreased by 4.11% to -$6.7 million in 2024, then slumped by 2877.84% to -$200.7 million in 2025, then jumped by 86.16% to -$27.8 million in 2026.
• The last three Profit After Tax figures came in at -$27.8 million (Q1 2026), -$200.7 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.

Peer Comparison